Literature DB >> 8629817

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

M A Tomai1, S J Gibson, L M Imbertson, R L Miller, P E Myhre, M J Reiter, T L Wagner, C B Tamulinas, J M Beaurline, J F Gerster.   

Abstract

Recently, a new class of immunomodulating agents, represented by the molecules imiquimod and R-842, has demonstrated potent antiviral and antitumor activities in animal models. In this study, another representative of this class, S-28463 (4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline- 1- ethanol) was evaluated for its immunomodulating and antiviral activities. S-28463 induced IFN and other cytokines in vivo in mice, rats, monkeys and in vitro in human peripheral blood mononuclear cell cultures. S-28463 showed potent antiviral activity against herpes simplex virus-challenged guinea pigs when given subcutaneously, dermally, or intravaginally 24 h before infection. Antiviral activity in guinea pigs correlated with the induction of serum 2',5'-oligoadenylate synthetase activity. Thus, S-28463, like the other imidazoquinolines, demonstrates potent antiviral and immunomodulating effects in a number of models.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8629817     DOI: 10.1016/0166-3542(95)00054-p

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  26 in total

1.  Innovative therapies in the treatment of keloids and hypertrophic scars.

Authors:  Martha H Viera; Sadegh Amini; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

2.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

3.  Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.

Authors:  Jonathan P Butchar; Payal Mehta; Steven E Justiniano; Kristan D Guenterberg; Sri-Vidya Kondadasula; Xiaokui Mo; Mahesh Chemudupati; Thirumala-Devi Kanneganti; Amal Amer; Natarajan Muthusamy; David Jarjoura; Clay B Marsh; William E Carson; John C Byrd; Susheela Tridandapani
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

4.  Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions.

Authors:  Kenneth H Fife; Tze-Chiang Meng; Daron G Ferris; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

Review 5.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

6.  Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.

Authors:  Jing Wang; Yuko Shirota; Defne Bayik; Hidekazu Shirota; Debra Tross; James L Gulley; Lauren V Wood; Jay A Berzofsky; Dennis M Klinman
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

7.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes.

Authors:  U Schultz; J Summers; P Staeheli; F V Chisari
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

9.  Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).

Authors:  J Moisan; W Wojciechowski; C Guilbault; C Lachance; S Di Marco; E Skamene; G Matlashewski; D Radzioch
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.

Authors:  Noah Craft; Ron Birnbaum; Natalie Quanquin; Marie Crisel B Erfe; Cara Quant; Jacquelyn Haskell; Kevin W Bruhn
Journal:  Clin Vaccine Immunol       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.